Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | F13A1 | P00488 | 1/20 | 0.36 |
| ▸ | TGM2 | P21980 | 1/20 | 0.36 |
| ▸ | TGM1 | P22735 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | PNMT | P11086 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12821513 | 1.00 | KDM4E (0.42) | KDM4EKMT2AF13A1TGM2TGM1 | |
| Hydrochloric Acid SCHEMBL27646236 | 0.98 | KDM4E (0.41) | KDM4EKMT2AF13A1TGM2TGM1 | |
| Ethane SCHEMBL27663543 | 0.96 | KMT2A (0.41) | KDM4EKMT2AF13A1TGM2TGM1 | |
| Cyclopropane SCHEMBL27924381 | 0.94 | KDM4E (0.47) | KDM4EKMT2AF13A1TGM2TGM1 | |
| SCHEMBL2091582 | 0.88 | KDM4E (0.35) | KDM4EKMT2AF13A1TGM2TGM1 | |
| SCHEMBL2185192 | 0.80 | CA1 (0.39) | KDM4EKMT2AF13A1TGM2TGM1 | |
| SCHEMBL5257406 | 0.80 | KMT2A (0.37) | KDM4EKMT2AMAPTMEN1ALDH1A1 | |
| SCHEMBL2185175 | 0.78 | CA1 (0.42) | KDM4EKMT2AMAPTMEN1USP2 | |
| SCHEMBL3598094 | 0.76 | KDM4E (0.46) | KDM4EKMT2AF13A1TGM2TGM1 | |
| SCHEMBL2186346 | 0.75 | CA12 (0.48) | KDM4EMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2694060-A1 | SUBSTITUTED 3-(1H-BENZO{D}IMIDAZOL-2-YL)-1H-INDAZOLE-ANALOGS AS INHIBITORS OF THE PDK1 KINASE | University of Utah Research Foundation (US) | 2014-02-12 | — | — | EP | claimed |
| US-8569511-B2 | Substituted 3-(1H-benzo[d]imidazol-2-yl)-1H-indazole analogs as inhibitors of the PDK1 kinase | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2013-10-29 | — | — | US | claimed |
| US-20120277229-A1 | SUBSTITUTED 3-(1H-BENZO[D]IMIDAZOL-2-YL)-1H-INDAZOLE ANALOGS AS INHIBITORS OF THE PDK1 KINASE | UNIVERSITY OF UTAH RESEARCH FOUNDATION | 2012-11-01 | — | — | US | claimed |
| WO-2012135799-A1 | SUBSTITUTED 3-(1H-BENZO{D}IMIDAZOL-2-YL)-1H-INDAZOLE-ANALOGS AS INHIBITORS OF THE PDK1 KINASE | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2012-10-04 | — | — | WO | claimed |
| EP-2346507-A1 | USE OF QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF VIRAL DISEASES | Boehringer Ingelheim International GmbH (DE) | 2011-07-27 | — | — | EP | claimed |
| WO-2010026029-A1 | USE OF QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF VIRAL DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-03-11 | — | — | WO | claimed |
| US-20070167440-A1 | Novel pyrrolidine compound and a process for preparing the same | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-07-19 | — | — | US | claimed |
| EP-1748980-A1 | PYRROLIDINE DERIVATIVES AS CB1-RECEPTOR ANTAGONISTS | TANABE SEIYAKU CO., LTD. (JP) | 2007-02-07 | — | — | EP | claimed |
| CN-1882529-A | Histone deacetylase inhibitors | METHYLGENE INC (CA) | 2006-12-20 | — | — | CN | claimed |
| WO-2006089871-A2 | DIPHENYLUREA DERIVATIVES USEFUL AS ERG CHANNEL OPENERS FOR THE TREATMENT OF CARDIAC ARRHYTHMIAS | NEUROSEARCH A/S (DK) | 2006-08-31 | — | — | WO | claimed |
| WO-2005115977-A1 | PYRROLIDINE DERIVATIVES AS CB1-RECEPTOR ANTAGONISTS | TANABE SEIYAKU CO., LTD. (JP) | 2005-12-08 | — | — | WO | claimed |
| CN-1642948-A | Piperazinyl-, piperidinyl-and morpholinyl derivatives as novel histone deacetylase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2005-07-20 | — | — | CN | claimed |
| WO-1995009158-A1 | TRICYCLIC DERIVATIVES | ZENECA LIMITED (GB) | 1995-04-06 | — | — | WO | claimed |
| WO-1994007869-A1 | QUINAZOLINE DERIVATIVES | ZENECA LIMITED (GB) | 1994-04-14 | — | — | WO | claimed |
| CN-109415392-A | Fluorochemical piperazines formamide | 3M创新有限公司 | 2019-03-01 | — | — | CN | disclosed |
| CN-105130973-B | 5- pyridine radicals -2- amino-benzo [d] oxazole derivatives and its preparation method and application | 海南国瑞堂中药制药有限公司 | 2018-05-01 | — | — | CN | disclosed |
| CN-103864753-A | Anti-HCV (hepatitis C) compound containing five-membered heteroaromatic ring structure, as well as preparation method and applications thereof | UNIV EAST CHINA NORMAL | 2014-06-18 | — | — | CN | disclosed |
| EP-0675114-A1 | OXAZOLINONE DERIVATIVE HAVING INTRACELLULAR PHOSPHOLIPASE A 2? INHIBITOR ACTIVITY | SHIONOGI & CO., LTD. (JP) | 1995-10-04 | — | — | EP | disclosed |
| WO-1995009158-A1 | TRICYCLIC DERIVATIVES | ZENECA LIMITED (GB) | 1995-04-06 | — | — | WO | disclosed |
| WO-1994007869-A1 | QUINAZOLINE DERIVATIVES | ZENECA LIMITED (GB) | 1994-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167440-A1 | Novel pyrrolidine compound and a process for preparing the same | CNR1, CNR2, OPRD1 | KDM4E 535/4885KMT2A 1998/4885F13A1 2783/4885 |
| US-20120277229-A1 | SUBSTITUTED 3-(1H-BENZO[D]IMIDAZOL-2-YL)-1H-INDAZOLE ANALOGS AS INHIBITORS OF THE PDK1 KINASE | PDK1, PDK3, PDK2 | KDM4E 1236/4885KMT2A 1793/4885F13A1 4503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.